Compare Uranium Energy Corp (UEC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs GeneDx Holdings Corp — how do they compare? Uranium Energy Corp trades at $9.19 (market cap $4.53B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Uranium Energy Corp is far larger — about 2.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Uranium Energy Corp for 37 Days and GeneDx Holdings Corp for 19 Days on average.
| UEC | WGS | |
|---|---|---|
Market Cap | $4.53B | $2.02B |
Volume | 10,888,578 | 734,640 |
Sector | Energy | Health |
52-Week High | $20.14 | $167.51 |
52-Week Low | $9.04 | $34.51 |
Typical Hold Time | 37 Days | 19 Days |
Enterprise Value | $4.03B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uranium Energy (UEC) trades at $9.14, down 3.48% in the last session, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37 million but posted a net loss of $137 million, reflecting ongoing operational challenges. Recent news highlights UEC's expansion to two operating mines and strong uranium pricing at $93.13 per pound, though production sustainability remains unproven. Technical indicators show bearish momentum with resistance at $10 and support at $9.
UEC presents a high-risk opportunity with significant analyst optimism (87.5% buy ratings) and a consensus price target of $16.06, offering 75% upside potential. However, persistent negative earnings, cash flow challenges, and dependence on uranium market dynamics pose substantial risks. Investors should weigh the company's strategic positioning in domestic uranium production against its current financial performance and execution risks.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
